Discounted Cash Flow (DCF) Analysis Levered
TG Therapeutics, Inc. (TGTX)
$15.72
-0.31 (-1.93%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.15 | 0.15 | 0.15 | 6.69 | 2.78 | 61.86 | 1,373.98 | 30,518.06 | 677,850.90 | 15,056,063.02 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -128.92 | -132.81 | -214.51 | -295.63 | -176.17 | -40,092 | -890,502.03 | -19,779,356.48 | -439,328,525.28 | -9,758,131,076.51 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.09 | -0.13 | -0.36 | -0.40 | -0.01 | -47.85 | -1,062.80 | -23,606.38 | -524,332.27 | -11,646,189.05 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -129.01 | -132.94 | -214.86 | -296.03 | -176.18 | -40,139.84 | -891,564.83 | -19,802,962.86 | -439,852,857.55 | -9,769,777,265.56 |
Weighted Average Cost Of Capital
| Share price | $ 15.72 |
|---|---|
| Beta | 2.290 |
| Diluted Shares Outstanding | 135.41 |
| Cost of Debt | |
| Tax Rate | -2.77 |
| After-tax Cost of Debt | 12.27% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 15.064 |
| Total Debt | 83.06 |
| Total Equity | 2,128.66 |
| Total Capital | 2,211.72 |
| Debt Weighting | 3.76 |
| Equity Weighting | 96.24 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.15 | 0.15 | 0.15 | 6.69 | 2.78 | 61.86 | 1,373.98 | 30,518.06 | 677,850.90 | 15,056,063.02 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -128.92 | -132.81 | -214.51 | -295.63 | -176.17 | -40,092 | -890,502.03 | -19,779,356.48 | -439,328,525.28 | -9,758,131,076.51 |
| Capital Expenditure | -0.09 | -0.13 | -0.36 | -0.40 | -0.01 | -47.85 | -1,062.80 | -23,606.38 | -524,332.27 | -11,646,189.05 |
| Free Cash Flow | -129.01 | -132.94 | -214.86 | -296.03 | -176.18 | -40,139.84 | -891,564.83 | -19,802,962.86 | -439,852,857.55 | -9,769,777,265.56 |
| WACC | ||||||||||
| PV LFCF | -34,916.36 | -674,620.32 | -13,034,365.87 | -251,837,498.73 | -4,865,762,276.05 | |||||
| SUM PV LFCF | -5,131,343,677.33 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 14.96 |
| Free cash flow (t + 1) | -9,965,172,810.88 |
| Terminal Value | -76,891,765,516.01 |
| Present Value of Terminal Value | -38,295,351,246.69 |
Intrinsic Value
| Enterprise Value | -43,426,694,924.02 |
|---|---|
| Net Debt | -19.24 |
| Equity Value | -43,426,694,904.78 |
| Shares Outstanding | 135.41 |
| Equity Value Per Share | -320,702,248.44 |